DakoCytomation to market LightUp's assays:
This article was originally published in Clinica
LightUp Technologies has granted Danish company, DakoCytomation co-exclusive rights to market and sell its line of ReSSQ infectious disease diagnostic products in Europe. The two companies will also collaborate on developing other products based on LightUp's proprietary assay technology. Huddinge, Sweden-based LightUp says its range of infectious disease diagnostics, based on nucleic acid detection, enables simpler and more accurate identification and quantification of disease generating organisms. The LightUp probe, inherent to the system, is designed to work with real-time PCR and can have several applications, including gene mapping and disease diagnostics.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.